Shuxin Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuxin Yan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Jintong Na
State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Therangstics, Guangxi Key Laboratory of Bio-targeting Therangstics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning 530021, China
1 shared publication - Pan Wu
College of Pharmacy, Guangxi Medical University, Nanning 530021, China
1 shared publication - Xiyu Liu
State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, Guangxi, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 7 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (2) , 248
Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
Traditional tumor treatments have the drawback of harming both tumor cells and normal cells, leading to significant systemic toxic side effects. As a result, there is a pressing need for targeted drug delivery methods that can specifically target cells or tissues. Currently, researchers have made significant progress in developing targeted drug delivery systems for tumor therapy using various targeting ligands. This review aims to summarize recent advancements in targeted drug delivery systems for tumor therapy, focusing on different targeting ligands such as folic acid, carbohydrates, peptides, aptamers, and antibodies. The review also discusses the advantages, challenges, and future prospects of these targeted drug delivery systems.
- 7 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (2) , 248
Top Cited PapersOpen AccessDifferent Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
Traditional tumor treatments have the drawback of harming both tumor cells and normal cells, leading to significant systemic toxic side effects. As a result, there is a pressing need for targeted drug delivery methods that can specifically target cells or tissues. Currently, researchers have made significant progress in developing targeted drug delivery systems for tumor therapy using various targeting ligands. This review aims to summarize recent advancements in targeted drug delivery systems for tumor therapy, focusing on different targeting ligands such as folic acid, carbohydrates, peptides, aptamers, and antibodies. The review also discusses the advantages, challenges, and future prospects of these targeted drug delivery systems.